Abstract
E1B55K-deleted dl1520 could selectively replicate in cancer cells and has been used in clinical trials as an antitumor agent. The mechanism of virus selective replication in cancer cells, including a possible role of p53, is unclear. Studies with established cancer cell lines have demonstrated that some cancer cells are resistant to dl1520 replication, regardless of the p53 status. Hep3B cells supported the E1b-deleted adenoviruses to replicate, whereas Saos2 cells were resistant to viral replication. We applied p53-null Hep3B and Saos2 cells as models to clarify the replication ability of E1B55K-deleted adenoviruses with different expression levels of E1a. We show that lower E1A expression in Saos2 may be the reason for the poor replication in some cancer cells due to the fact that E1a promoter was less activated in Saos2 than in Hep3B. We also demonstrate that the E1B55K protein can increase E1A expression in Saos2 cells for efficient virus replication. In addition, the upstream regions of the E1a promoter have transcriptional activity in Hep3B cells but not in Saos2 cells. The viral E1B55K protein may activate cancer cellular factor(s) that targets the upstream regions of the E1a gene to increase its expression. This is the first study demonstrating that E1B55K protein affects the E1A production levels that is related to cancer selective replication. Our studies have suggested that increase of E1A expression from E1b-deleted adenoviruses may enhance killing cancer cells that otherwise are resistant to viral replication.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- WT:
-
wild type
- MOI:
-
multiplicity of infection
- PFU:
-
plaque-forming unit(s)
- CPE:
-
cytopathic effect
- CMV:
-
cytomegalovirus
References
Zhao T, Rao XM, Xie X, Li L, Thompson TC, McMasters KM et al. Adenovirus with insertion-mutated E1A selectively propagates in liver cancer cells and destroys tumors in vivo. Cancer Res 2003; 63: 3073–3078.
Rao XM, Tseng MT, Zheng X, Dong Y, Jamshidi-Parsian A, Thompson TC et al. E1A-induced apoptosis does not prevent replication of adenoviruses with deletion of E1b in majority of infected cancer cells. Cancer Gene Ther 2004; 11: 585–593.
Hallenbeck PL, Chang YN, Hay C, Golightly D, Stewart D, Lin J et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721–1733.
Kim J, Lee B, Kim JS, Yun CO, Kim JH, Lee YJ et al. Antitumoral effects of recombinant adenovirus YKL-1001, conditionally replicating in alpha-fetoprotein-producing human liver cancer cells. Cancer Lett 2002; 180: 23–32.
Takahashi M, Sato T, Sagawa T, Lu Y, Sato Y, Iyama S et al. E1B-55K-deleted adenovirus expressing E1A-13S by AFP-enhancer/promoter is capable of highly specific replication in AFP-producing hepatocellular carcinoma and eradication of established tumor. Mol Ther 2002; 5: 627–634.
Ren XW, Liang M, Meng X, Ye X, Ma H, Zhao Y et al. A tumor-specific conditionally replicative adenovirus vector expressing TRAIL for gene therapy of hepatocellular carcinoma. Cancer Gene Ther 2005 (in press).
Kurihara T, Brough DE, Kovesdi I, Kufe DW . Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. J Clin Invest 2000; 106: 763–771.
Hernandez-Alcoceba R, Pihalja M, Wicha MS, Clarke MF . A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. Hum Gene Ther 2000; 11: 2009–2024.
Sarkar D, Su ZZ, Vozhilla N, Park ES, Gupta P, Fisher PB . Dual cancer-specific targeting strategy cures primary and distant breast carcinomas in nude mice. Proc Natl Acad Sci USA 2005; 102: 14034–14039.
Dwyer RM, Bergert ER, O'Connor MK, Gendler SJ, Morris JC . In vivo radioiodide imaging and treatment of breast cancer xenografts after MUC1-driven expression of the sodium iodide symporter. Clin Cancer Res 2005; 11: 1483–1489.
Fuerer C, Iggo R . Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. Gene Therapy 2002; 9: 270–281.
Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT . Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res 2002; 62: 4663–4670.
Banerjee NS, Rivera AA, Wang M, Chow LT, Broker TR, Curiel DT et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther 2004; 3: 437–449.
Peter I, Graf C, Dummer R, Schaffner W, Greber UF, Hemmi S . A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Therapy 2003; 10: 530–539.
Liu Y, Ye T, Sun D, Maynard J, Deisseroth A . Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther 2004; 15: 637–647.
Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW . Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559–2563.
Yu DC, Chen Y, Seng M, Dilley J, Henderson DR . The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res 1999; 59: 4200–4203.
Yu DC, Chen Y, Dilley J, Li Y, Embry M, Zhang H et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. Cancer Res 2001; 61: 517–525.
Chen Y, DeWeese T, Dilley J, Zhang Y, Li Y, Ramesh N et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. Cancer Res 2001; 61: 5453–5460.
DeWeese TL, van der Poel H, Li S, Mikhak B, Drew R, Goemann M et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res 2001; 61: 7464–7472.
Dilley J, Reddy S, Ko D, Nguyen N, Rojas G, Working P et al. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity. Cancer Gene Ther 2005; 12: 715–722.
Haviv YS, Curiel DT . Engineering regulatory elements for conditionally-replicative adeno-viruses. Curr Gene Ther 2003; 3: 357–385.
Nettelbeck DM . Virotherapeutics: conditionally replicative adenoviruses for viral oncolysis. Anticancer Drugs 2003; 14: 577–584.
Kanerva A, Hemminki A . Modified adenoviruses for cancer gene therapy. Int J Cancer 2004; 110: 475–480.
Post DE, Khuri FR, Simons JW, Van Meir EG . Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 2003; 14: 933–946.
Barker DD, Berk AJ . Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 1987; 156: 107–121.
Bischoff JR, Kirn DH, Williams A, Heise C, Horn S, Muna M et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 1996; 274: 373–376.
Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH . ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med 1997; 3: 639–645.
Rogulski KR, Freytag SO, Zhang K, Gilbert JD, Paielli DL, Kim JH et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res 2000; 60: 1193–1196.
Dix BR, Edwards SJ, Braithwaite AW . Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J Virol 2001; 75: 5443–5447.
Geoerger B, Grill J, Opolon P, Morizet J, Aubert G, Terrier-Lacombe MJ et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. Cancer Res 2002; 62: 764–772.
Hobom U, Dobbelstein M . E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. J Virol 2004; 78: 7685–7697.
O'Shea CC, Johnson L, Bagus B, Choi S, Nicholas C, Shen A et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. Cancer Cell 2004; 6: 611–623.
Steegenga WT, Riteco N, Bos JL . Infectivity and expression of the early adenovirus proteins are important regulators of wild-type and DeltaE1B adenovirus replication in human cells. Oncogene 1999; 18: 5032–5043.
Edwards SJ, Dix BR, Myers CJ, Dobson-Le D, Huschtscha L, Hibma M et al. Evidence that replication of the antitumor adenovirus ONYX-015 is not controlled by the p53 and p14(ARF) tumor suppressor genes. J Virol 2002; 76: 12483–12490.
Bressac B, Galvin KM, Liang TJ, Isselbacher KJ, Wands JR, Ozturk M et al. Abnormal structure and expression of p53 gene in human hepatocellular carcinoma. Proc Natl Acad Sci USA 1990; 87: 1973–1977.
Farshid M, Tabor E . Expression of oncogenes and tumor suppressor genes in human hepatocellular carcinoma and hepatoblastoma cell lines. J Med Virol 1992; 38: 235–239.
Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10: 5772–5781.
Chandar N, Billig B, McMaster J, Novak J . Inactivation of p53 gene in human and murine osteosarcoma cells. Br J Cancer 1992; 65: 208–214.
Morsy MA, Alford EL, Bett A, Graham FL, Caskey CT . Efficient adenoviral vector mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J Clin Invest 1993; 92: 1580–1586.
Zhou H, Beaudet A . A new vector system with inducible cell line E2T for production of safer and higher titer adenoviral vectors. Virology 2000; 275: 348–357.
Zhou H, O'Neal W, Morral N, Beaudet AL . Development of a complementing cell line and a system for construction of adenovirus vectors with E1 and E2a deleted. J Virol 1996; 70: 7030–7038.
Sarnow P, Sullivan CA, Levine AJ . A monoclonal antibody detecting the adenovirus type 5-E1b-58kD tumor antigen: characterization of the E1b-58kD tumor antigen in adenovirus-infected and -transformed cells. Virology 1982; 120: 510–517.
Graham FL . Manipulation of adenovirus vectors. In: Murray EJ (ed). Methods in Molecular Biology, Vol. 7. The Humana Press Inc.: Clifton, NJ, 1991, pp 109–128.
Bett AJ, Haddara W, Prevec L, Graham FL . An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc Natl Acad Sci USA 1994; 91: 8802–8806.
Shenk T . Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM (eds). Fields Virology, Vol. 2. Lippincott Williams & Wilkins: Philadelphia, PA, 2001, pp 2265–2300.
Osborne TF, Gaynor RB, Berk AJ . The TATA homology and the mRNA 5′ untranslated sequence are not required for expression of essential adenovirus E1A functions. Cell 1982; 29: 139–148.
Osborne TF, Berk AJ . Far upstream initiation sites for adenovirus early region 1A transcription are utilized after the onset of viral DNA replication. J Virol 1983; 45: 594–599.
Frisch SM, Mymryk JS . Adenovirus-5 E1A: paradox and paradigm. Nat Rev Mol Cell Biol 2002; 3: 441–452.
Ries S, Korn WM . ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus. Br J Cancer 2002; 86: 5–11.
Biederer C, Ries S, Brandts CH, McCormick F . Replication-selective viruses for cancer therapy. J Mol Med 2002; 80: 163–175.
Kirn D, Martuza RL, Zwiebel J . Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 2001; 7: 781–787.
O'Shea CC, Soria C, Bagus B, McCormick F . Heat shock phenocopies E1B-55K late functions and selectively sensitizes refractory tumor cells to ONYX-015 oncolytic viral therapy. Cancer Cell 2005; 8: 61–74.
Mal A, Poon RY, Howe PH, Toyoshima H, Hunter T, Harter ML . Inactivation of p27Kip1 by the viral E1A oncoprotein in TGFbeta-treated cells. Nature 1996; 380: 262–265.
Whalen SG, Marcellus RC, Whalen A, Ahn NG, Ricciardi RP, Branton PE . Phosphorylation within the transactivation domain of adenovirus E1A protein by mitogen-activated protein kinase regulates expression of early region 4. J Virol 1997; 71: 3545–3553.
Acknowledgements
We thank Dr Donald Miller for helpful discussion and support. This work was supported by NIH Grant R01 CA90784-01A1 (KMM), Research Grant G030983 from Kentucky Lung Cancer Research Program, and Pilot Grant from Brown Cancer Center (HSZ). We thank other members in our laboratory for their help in this study, including Min Wang, Yanbin Dong, Hongying Hao, and Jorge G Gutierrez.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Zheng, X., Rao, XM., Snodgrass, C. et al. Selective replication of E1B55K-deleted adenoviruses depends on enhanced E1A expression in cancer cells. Cancer Gene Ther 13, 572–583 (2006). https://doi.org/10.1038/sj.cgt.7700923
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700923
Keywords
This article is cited by
-
Oncolytic adenovirus targeting cyclin E overexpression repressed tumor growth in syngeneic immunocompetent mice
BMC Cancer (2015)
-
Virotherapy targeting cyclin E overexpression in tumors with adenovirus-enhanced cancer-selective promoter
Journal of Molecular Medicine (2015)
-
Combination of autophagy inducer rapamycin and oncolytic adenovirus improves antitumor effect in cancer cells
Virology Journal (2013)
-
Combinatory cytotoxic effects produced by E1B-55kDa-deleted adenoviruses and chemotherapeutic agents are dependent on the agents in esophageal carcinoma
Cancer Gene Therapy (2010)